Published in
American Association for the Advancement of Science, Science Translational Medicine, 451(10), 2018
DOI: 10.1126/scitranslmed.aar5429
Links
Tools
LRRK2 activation in idiopathic Parkinson’s disease
Journal article published in 2018 by
Roberto Di Maio 
,
Eric K. Hoffman ,
Emily M. Rocha,
Matthew T. Keeney ,
Laurie H. Sanders ,
Briana R. De Miranda ,
Alevtina Zharikov ,
Amber Van Laar ,
Antonia F. Stepan,
Thomas A. Lanz,
Julia K. Kofler ,
Edward A. Burton ,
Dario R. Alessi ,
Teresa G. Hastings ,
J. Timothy Greenamyre
,
Eric K. Hoffman ,
Emily M. Rocha,
Matthew T. Keeney ,
Laurie H. Sanders ,
Briana R. De Miranda ,
Alevtina Zharikov ,
Amber Van Laar ,
Antonia F. Stepan,
Thomas A. Lanz,
Julia K. Kofler ,
Edward A. Burton ,
Dario R. Alessi ,
Teresa G. Hastings ,
J. Timothy Greenamyre
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Wild-type LRRK2 is activated in nigrostriatal dopamine neurons in idiopathic Parkinson’s disease and plays a pathogenic role in this neurodegenerative disorder.